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efore the 1980s, cardiac hypertrophy was thought to be a
ompensatory response of the heart to hemodynamic over-
oad that normalized left ventricular (LV) wall stress and
ermitted individual cardiac myocytes to operate under a
ormal load. However, during the last 3 decades, we have
ncreasingly recognized that the cellular remodeling that
ccurs during compensatory hypertrophy, including altered
ene expression, can be deleterious and can contribute to the
rogression to heart failure. Prominent among the changes
n gene expression in the hypertrophic response to pressure
verload are those responsible for intracellular calcium
omeostasis. This includes decreased levels of the sarcoplas-
ic reticulum Ca adenosine triphosphatase, the protein
esponsible for removal during diastole of 75% of the
alcium present in the cardiomyocyte cytoplasm. Further-
ore, clinical investigations have supported the contention
hat cardiac hypertrophy that occurs to compensate for
ressure overload, such as is seen in essential hypertension,
s adversely prognostic (1,2).
See page 207
More recently, investigations of the response of animal
odels using transgenic mice undergoing hemodynamic
tress have allowed us to begin to understand that the
ntracellular signaling that initiates the compensatory hy-
ertrophic response can also be responsible for the progres-
ion to heart failure. These studies have shown that the
alcium-sensitive phosphatase calcineurin and its activation
f the nuclear factor of activated T cells is a critical signaling
athway for pathologic cardiac hypertrophy (3,4). Trans-
enic mice deficient in calcineurin activity are resistant to
any of the hypertrophic stimuli that we recognize as also
eading to heart failure, such as pressure overload and
eurohormonal stimulation (5).
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assachusetts.Animal models, such as the thoracic aortic constriction
TAC) model used by Nagayama et al. (6) in this issue of
he Journal, can provide important insights into both the
hysiology by which hypertrophy leads to heart failure, and
he signaling pathways that are altered during this transi-
ion. Myocardial signaling through the guanylate cyclase–
yclic guanosine monophosphate pathway has been shown
o inhibit gene expression associated with the development
f hypertrophy as a result of either adrenergic stimulation or
ressure overload (7). This raised the possibility that the
nzyme type 5 phosphodiesterase (PDE5), which hydro-
yzes the intracellular second messenger cyclic guanosine
onophosphate, could inhibit the development of hyper-
rophy. The PDE5 inhibitor sildenafil, which is used
linically for the treatment of either erectile dysfunction or
ulmonary arterial hypertension, was shown to prevent or
mprove the development of hypertrophy in TAC mice
hen initiated at the time or early after the thoracic
onstrictor was placed (8). Deterioration in contractile
ysfunction was also prevented by PDE5 inhibition.
Of course, in treating human disease, we usually do not
ave the opportunity to intervene at the time that a
athological stress begins. Rather, patients are usually seen
fter the symptoms and signs of disease have already become
stablished. Therefore, in the current study, Nagayama et al.
6) used mice in which hypertrophy, dilation, and systolic
ysfunction had been established after 3 weeks of TAC.
atriuretic peptide gene expression was increased, a marker
or the adverse cardiac remodeling that was occurring.
ildenafil treatment halted the progression of LV dilation
nd systolic dysfunction that was seen in untreated animals,
nd natriuretic peptide gene expression did not increase
urther, despite the fact that TAC remained. The increase
n calcineurin protein expression and regulator gene activity
bserved as a result of TAC did not progress in mice treated
ith sildenafil. It is intriguing that translocation of protein
inase C-, an important step in the regulation of enzy-
atic sarcolemmal calcium reuptake, was altered by silde-
afil treatment in a manner that may be expected to improve
iastolic cardiac relaxation.
From the perspective of the clinician, the study by
agayama et al. (6) represents hope that pharmacological
ntervention in an animal model of adverse hypertrophy may
e translatable to the treatment of human heart failure in
he foreseeable future. Previous efforts to reverse the adverse
unctional consequences of cardiac hypertrophy with
-adrenergic receptor antagonists and inhibitors of the
enin-angiotensin-aldosterone system have been disap-
ointing, particularly when initiated in patients with estab-
ished disease. In this study, not only were the adverse
unctional consequences of established cardiac hypertrophy
eversed by PDE5 inhibition, but also the gene expression
hat is thought to lead to adverse cardiac remodeling was
nhibited. The clinical implications of these findings are
eing explored in the National Heart, Lung, and Blood
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ailure and a normal LV ejection fraction are being random-
zed to chronic sildenafil therapy or placebo, and indexes of
unctional capacity and myocardial remodeling are being
ssessed. The findings of investigations such as the current
tudy by Nagayama et al. (6) encourage the design of clinical
nvestigations and of the innovative use of agents that were
nitially thought to have very different effects.
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